This review provides a systematic review of the dengue vaccines data available from the last five years highlighting significant progress in vaccine development, efficacy, and safety and TAK-003 showed the greatest efficacy against hospitalized and symptomatic Dengue patients, reducing risk by 85% (RR 0.15; 95% CI 0.07-0.33).
No takes yet. Share an insight, caveat, or question.
Kant et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: